Ayrton Capital-led group reports 9.72% Genprex (GNPX) stake via warrants
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants. This position represents 9.72% of the common stock, calculated using 2,318,894 shares outstanding as of November 19, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be issued on exercise at any time. The investors certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex.
Positive
- None.
Negative
- None.
FAQ
What stake in Genprex (GNPX) is reported in this Schedule 13G?
The filing reports beneficial ownership of 249,788 Genprex common shares, equal to 9.72% of the class. This percentage is based on 2,318,894 shares outstanding as of November 19, 2025, plus the shares issuable upon warrant exercise.
Who are the reporting persons in the Genprex (GNPX) Schedule 13G?
The reporting persons are Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri. Alto holds the Genprex securities, Ayrton acts as investment manager, and Khatri is the managing member of Ayrton and a director of the fund.
How is the 9.72% Genprex (GNPX) ownership by Ayrton Capital and affiliates calculated?
The 9.72% figure is calculated using 2,318,894 Genprex common shares outstanding as of November 19, 2025, plus 249,788 additional shares issuable upon exercise of warrants held by the reporting persons, as described in the ownership section.
What securities do Ayrton Capital and Alto Opportunity Master Fund hold in Genprex (GNPX)?
They report 249,788 shares of Genprex common stock issuable upon exercise of certain warrants. These warrant-based shares form the entire reported beneficial ownership position and are subject to a 9.99% beneficial ownership blocker limitation.
What is the 9.99% beneficial ownership blocker mentioned for Genprex (GNPX)?
The filing states that the warrant shares are subject to a 9.99% beneficial ownership blocker. This provision limits the number of shares that can be issued upon warrant exercise so the holders do not exceed 9.99% beneficial ownership at any time.
Are Ayrton Capital and its affiliates seeking control of Genprex (GNPX)?
The reporting persons certify the Genprex securities were acquired and are held in the ordinary course of business. They state the holdings were not acquired and are not held to change or influence control of Genprex, except for limited nomination-related activities.